0000000000202315

AUTHOR

Mercè Roqué

showing 8 related works from this author

Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction.

2016

Abstract Background Comorbid elderly patients with non-ST-elevation myocardial infarction (non-STEMI) are underrepresented in randomized trials and undergo fewer cardiac catheterizations according to registries. Our aim was to compare the conservative and invasive strategies in these patients. Methods Randomized multicenter study, including 106 patients (January 2012–March 2014) with non-STEMI, over 70 years and with comorbidities defined by at least two of the following: peripheral artery disease, cerebral vascular disease, dementia, chronic pulmonary disease, chronic renal failure or anemia. Patients were randomized to invasive (routine coronary angiogram, n = 52) or conservative (coronar…

Malemedicine.medical_specialtyCardiac Catheterizationmedicine.medical_treatmentComorbidityKaplan-Meier Estimate030204 cardiovascular system & hematologyRevascularizationCoronary Angiography03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicineMedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesRegistriesAngioplasty Balloon CoronaryProspective cohort studyNon-ST Elevated Myocardial InfarctionCardiac catheterizationAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelCardiovascular Agentsmedicine.diseaseComorbidityTreatment OutcomeSpainHeart failureCardiovascular agentCardiologyFemalebusinessEuropean journal of internal medicine
researchProduct

Usefulness of delta troponin for diagnosis and prognosis assessment of non-ST-segment elevation acute chest pain.

2014

The additional diagnostic and prognostic information provided by delta high-sensitivity troponin T (hs-cTnT) in patients with acute chest pain and hs-cTnT elevation remains unclear.The study group consisted of 601 patients presenting at the emergency department with non-ST-segment elevation acute chest pain and hs-cTnT elevation after two determinations (admission and within the first six hours). Maximum hs-cTnT and delta hs-cTnT (absolute or percentage change between the two measurements) were considered. Cutoff values were optimized using the quartile distribution for the endpoints. The endpoints were diagnostic (significant stenosis in the coronary angiogram) and prognostic (death or rec…

Malemedicine.medical_specialtyChest Pain030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineChest pain03 medical and health sciences0302 clinical medicineTroponin TInternal medicinemedicineST segmentHumans030212 general & internal medicineMyocardial infarctionAgedTroponin TbiologySurrogate endpointbusiness.industryGeneral MedicineEmergency departmentMiddle Agedmedicine.diseasePrognosisTroponinQuartileCardiologybiology.proteinFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEuropean heart journal. Acute cardiovascular care
researchProduct

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction

2020

Objective Primary percutaneous coronary intervention (P-PCI) has demonstrated its efficacy in patients with ST segment elevation myocardial infarction (STEMI). However, patients with STEMI >= 75 years receive less P-PCI than younger patients despite their higher in-hospital morbimortality. The objective of this analysis was to determine the effectiveness of P-PCI in patients with STEMI >= 75 years. Methods We included 979 patients with STEMI >= 75 years, from the ATencion HOspitalaria del Sindrome coronario study, a registry of 8142 consecutive patients with acute coronary syndrome admitted at 31 Spanish hospitals in 2014-2016. We calculated a propensity score (PS) for the indication of P-P…

MaleTime FactorsPercutaneoussistema de registrosmedicine.medical_treatmenthumanosComorbidityCoronary Artery Disease030204 cardiovascular system & hematologyLogistic regression0302 clinical medicineRecurrenceRisk Factorsevaluación de riesgosST segmentRegistries1506030212 general & internal medicineMyocardial infarctionAged 80 and overancianocoronary intervention (PCI)resultado del tratamientoCardiogenic shockAge FactorsShockstemiTreatment Outcomesurgical procedures operativeCardiologyFemaleAcute coronary syndromeCardiology and Cardiovascular MedicineStemiAcute coronary syndromemedicine.medical_specialtyShock CardiogenicPulmonary EdemaRisk Assessmentacute coronary syndromeedema pulmonar03 medical and health sciencesfactores de tiempoPercutaneous Coronary Interventionchoquecirugía coronaria percutáneaInternal medicinemedicinefactores de riesgoHumanscardiovascular diseasesAgedCoronary intervention (PCI)business.industryPercutaneous coronary interventionmedicine.diseaseSpainPropensity score matchingST Elevation Myocardial InfarctionbusinessrecurrenciaOpen Heart
researchProduct

Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

2017

Abstract Introduction and objectives The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1. Methods Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4 mg/dL on admission will be randomized to: a) standard diuretic str…

medicine.medical_specialtymedicine.medical_treatmentWater-Electrolyte ImbalanceRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyPatient Care Planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFurosemideInternal medicineHumansMedicine030212 general & internal medicineDiureticsIntensive care medicineHeart FailureCreatinineCardio-Renal Syndromebusiness.industryClinical study designChlorthalidoneMembrane ProteinsGeneral Medicinemedicine.diseasePathophysiologyAcetazolamideClinical trialchemistryCA-125 AntigenCreatinineHeart failureAcute DiseaseCardiologyDiureticbusinessRevista Española de Cardiología (English Edition)
researchProduct

Estrategias diuréticas en insuficiencia cardiaca aguda con disfunción renal: terapia convencional frente a guiada por el antígeno carbohidrato 125. D…

2017

Resumen Introduccion y objetivos El tratamiento optimo de pacientes con insuficiencia cardiaca aguda (ICA) y sindrome cardiorrenal tipo 1 (SCR-1) no esta bien definido. La hipoperfusion arterial y la congestion venosa tienen un papel fundamental en la fisiopatologia del SCR-1. El antigeno carbohidrato 125 (CA125) ha emergido como marcador indirecto de sobrecarga de volumen en la ICA. El objetivo de este estudio es evaluar la utilidad del CA125 para el ajuste del tratamiento diuretico de pacientes con SCR-1. Metodos Ensayo clinico multicentrico, abierto y paralelo, que incluye a pacientes con ICA y creatinina ≥ 1,4 mg/dl al ingreso, aleatorizados a: a)  estrategia convencional: titulacion ba…

03 medical and health sciences0302 clinical medicinebusiness.industryMedicine030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct

Clinical Evaluation Versus Undetectable High-Sensitivity Troponin for Assessment of Patients With Acute Chest Pain.

2016

Decision-making in acute chest pain remains challenging despite normal (below ninety-ninth percentile) high-sensitivity troponin (hs-cTn). Some studies suggest that undetectable hs-cTn, far below the ninety-ninth percentile, might rule out acute coronary syndrome. We investigated clinical data in comparison to undetectable hs-cTnT. The study comprised 682 patients (November 2010 to September 2011) presenting at the emergency department with chest pain and normal hs-cTnT (14 ng/l). The main end point was major adverse cardiac events (MACE: death, myocardial infarction, readmission for unstable angina, or revascularization) at a 4-year median follow-up; secondary end point was 30-day MACE. A …

MalePercentileAcute coronary syndromemedicine.medical_specialtyChest PainClinical Decision-Making030204 cardiovascular system & hematologyChest painSeverity of Illness IndexDiagnosis Differential03 medical and health sciencesElectrocardiography0302 clinical medicineTroponin TInternal medicineSeverity of illnessMedicineHumans030212 general & internal medicineProspective StudiesProspective cohort studyhealth care economics and organizationsbiologymedicine.diagnostic_testbusiness.industryIncidenceEmergency departmentMiddle Agedmedicine.diseasePrognosisTroponinAcute PainSpainbiology.proteinCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEmergency Service HospitalElectrocardiographyBiomarkersFollow-Up StudiesThe American journal of cardiology
researchProduct

Mobilization of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: Time-course after acute myocardial infarction and s…

2015

The mobilization pattern and functionality of endothelial progenitor cells after an acute ischemic event remain largely unknown. The aim of our study was to characterize and compare the short- and long-term mobilization of endothelial progenitor cells and circulating endothelial cells after acute myocardial infarction or atherothrombotic stroke, and to determine the relationship between these cell counts and plasma concentrations of vascular cell adhesion molecule (VCAM-1) and Von Willebrand factor (VWF) as surrogate markers of endothelial damage and inflammation. In addition, we assessed whether endothelial progenitor cells behave like functional endothelial cells. We included 150 patients…

AdultMaleVascular Endothelial Growth Factor ACD31medicine.medical_specialtyTime FactorsMyocardial InfarctionCD34Vascular Cell Adhesion Molecule-1Cell CountInflammationSeverity of Illness IndexEndothelial progenitor cellImmunophenotypingchemistry.chemical_compoundVasculogenesisRisk FactorsInternal medicinevon Willebrand FactormedicineHumansProspective StudiesProgenitor cellMolecular BiologyCells CulturedAgedEndothelial Progenitor Cellsbusiness.industryEndothelial CellsMiddle AgedStrokeVascular endothelial growth factorPhenotypeEndocrinologychemistryCase-Control StudiesCardiologyCD146Femalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of Molecular and Cellular Cardiology
researchProduct